University of Pittsburgh

MindMaze Therapeutics is sharpening its focus on neurotherapeutics after completing its organizational simplification, while the revised CHF 8 million Neuro.io equity financing schedule puts funding, liquidity and commercial execution in focus. Representative image.

Medical Devices & Diagnostics

MindMaze Therapeutics has finished its portfolio reset, but why is half of the CHF 8m Neuro.io financing still pending?

by Pallavi Madhiraju
August 10, 2026
0 Comments

MindMaze Therapeutics finishes its neurology refocus while CHF 4 million of Neuro.io funding shifts to September and November. See what comes next.

Read More

Pharma & Biotech

Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing

by Pallavi Madhiraju
May 27, 2026
0 Comments

Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.

Read More